News of the Day

The PBAC Executive operates with no terms of reference. There are no published agendas or outcomes. It has no standing under the PBAC's legislated decision-making framework but it does issue advice and feedback to sponsors through the Department of Health.

The CSL share price topped $300 for the first time yesterday marking a remarkable rise of more than 50 per cent over the past year.

The federal government has moved to fundamentally simplify and 'slim-down' the reform of the supply chain payment system after more than two years of negotiations with the sector that have consistently hit a dead-end.

The explicit linking of R&D, reimbursement of a product and industry development policy through manufacturing marks a new development in the promotion of biopharmaceutical innovation.

Much of the discussion over transparency is focused on Public Summary Documents. The PBAC considered 1,600 pages of discussant presentations at its November 2019 meeting - these documents remain secret.

Manufacturers and medicine suppliers have announced financial and charitable commitments topping several million dollars in support of communities impacted by bushfires.

The industry will gather in Sydney later today to mark the retirement of Deborah Monk, who is departing Medicines Australia after thirty years with the association.

New documents released by PHARMAC show the agency knew of deaths linked to the forced switch of an anti-epilepsy medicine but delayed telling patients and the public.

Pfizer spinout Upjohn has announced it will not be sticking with exclusive direct distribution and is returning to a traditional model of wholesale distribution from February next year.

The annual PBS Expenditure and Prescriptions report reveals many things about the PBS, including some important detail that highlights the 'tensions' building within the program.

The BioPharmaDispatch analysis of the recently released annual PBS Expenditure and Prescriptions report has confirmed the challenge of assessing the scheme based on spending growth but confirms how it has effectively transformed into two programs.

Stakeholder groups are expecting to receive invitations this week to participate in the working group to support the development of the scope and terms of reference for the review of the National Medicines Policy.